Mariotti S, Anelli S, Ruf J, Bechi R, Czarnocka B, Lombardi A, Carayon P, Pinchera A
Cattedra di Endocrinologia e Medicina Costituzionale, Istituto di Metodologia Clinica e Medicina del Lavoro, University of Pisa, Italy.
J Clin Endocrinol Metab. 1987 Nov;65(5):987-93. doi: 10.1210/jcem-65-5-987.
Recent evidence indicates that human thyroid peroxidase (TPO) has most of the characteristics of the thyroid microsomal antigen. The question of whether TPO accounts for part or all of the antigenic activity recognized by circulating anti-microsomal antigen autoantibody (anti-M Ab) remains to be determined. The availability of an anti-TPO monoclonal antibody and of a highly purified TPO preparation allowed the development of specific and sensitive radioassays for anti-TPO autoantibody (anti-TPO Ab). In this study we compared anti-M Ab and anti-TPO Ab levels in serum from 128 subjects, including patients with Hashimoto's thyroiditis (n = 31), idiopathic myxedema (n = 11), hyperthyroid Graves' disease (n = 45), miscellaneous nonautoimmune thyroid disorders (n = 9), and normal subjects (n = 32). Anti-M Ab and anti-TPO Ab were measured by radioimmunological methods employing two different assay designs: 1) competitive radioassay (CR), based on the inhibition of radioiodinated antibody binding to human thyroid microsomes coated on microtiter wells, using a) [125I]immunoglobulin G (IgG) containing a high anti-M Ab titer (for anti-M Ab determinations), or b) [125I]anti-TPO monoclonal antibody (for anti-TPO Ab); and 2) sandwich immunoradiometric assay (IRMA) using microtiter wells coated with thyroid microsomes (for anti-M Ab determinations) or immunoaffinity-purified TPO (for anti-TPO Ab determinations) and [125I]anti-human IgG antibody. Anti-M Ab also was measured by passive hemagglutination. Anti-M Ab titers by PH closely correlated with anti-TPO Ab levels whether assayed by IRMA (r = 0.905; P less than 0.00001) or CR (r = 0.922; P less than 0.00001). Even closer correlations were found when anti-M Ab and anti-TPO Ab both were measured by the same type of radioassay procedure (IRMA, r = 0.945 and P less than 0.00001; CR, r = 0.957 and P less than 0.00001). No differences in the correlation between anti-M Ab and anti-TPO Ab results were found when the data in patients with different autoimmune thyroid disorders were analyzed separately. Further and more direct evidence for the identity of anti-M Ab and anti-TPO Ab was provided by the ability of purified TPO to completely inhibit the binding to thyroid microsomes of radioiodinated IgG preparations containing high anti-M Ab titers. In conclusion, our results provide strong support for the concept that TPO accounts for virtually all of the antigenic determinants reacting with the autoantibodies commonly termed anti-M antibodies.(ABSTRACT TRUNCATED AT 400 WORDS)
近期证据表明,人甲状腺过氧化物酶(TPO)具有甲状腺微粒体抗原的大部分特征。TPO是否构成循环抗微粒体抗原自身抗体(抗-M抗体)所识别的部分或全部抗原活性问题仍有待确定。抗TPO单克隆抗体和高度纯化的TPO制剂的可得性使得能够开发针对抗TPO自身抗体(抗-TPO抗体)的特异性和灵敏放射测定法。在本研究中,我们比较了128名受试者血清中的抗-M抗体和抗-TPO抗体水平,这些受试者包括桥本甲状腺炎患者(n = 31)、特发性黏液性水肿患者(n = 11)、甲状腺功能亢进的格雷夫斯病患者(n = 45)、其他非自身免疫性甲状腺疾病患者(n = 9)以及正常受试者(n = 32)。采用两种不同的测定设计通过放射免疫方法测量抗-M抗体和抗-TPO抗体:1)竞争性放射测定法(CR),基于抑制放射性碘化抗体与包被在微量滴定板孔上的人甲状腺微粒体的结合,使用a)含有高抗-M抗体效价的[125I]免疫球蛋白G(IgG)(用于抗-M抗体测定),或b)[125I]抗-TPO单克隆抗体(用于抗-TPO抗体);2)夹心免疫放射测定法(IRMA),使用包被有甲状腺微粒体(用于抗-M抗体测定)或免疫亲和纯化的TPO(用于抗-TPO抗体测定)的微量滴定板孔以及[125I]抗人IgG抗体。抗-M抗体也通过被动血凝试验进行测量。无论通过IRMA(r = 0.905;P小于0.00001)还是CR(r = 0.922;P小于0.00001)测定,通过PH测得的抗-M抗体效价与抗-TPO抗体水平密切相关。当抗-M抗体和抗-TPO抗体都通过同一种放射测定程序测量时,发现相关性更强(IRMA,r = 0.945且P小于0.00001;CR,r = 0.957且P小于0.00001)。当分别分析不同自身免疫性甲状腺疾病患者的数据时,未发现抗-M抗体和抗-TPO抗体结果之间的相关性存在差异。纯化的TPO能够完全抑制含有高抗-M抗体效价的放射性碘化IgG制剂与甲状腺微粒体的结合,这为抗-M抗体和抗-TPO抗体的一致性提供了进一步且更直接的证据。总之,我们的结果为TPO几乎构成了与通常称为抗-M抗体的自身抗体发生反应的所有抗原决定簇这一概念提供了有力支持。(摘要截短至400字)